CXCL12 and pancreatic neoplasm: Using propidium iodide staining, we measured a ∼50% decrease in the percent of CXCL12-expressing pancreatic cancer cells in the G2 phase of cell cycle, compared to GFP-expressing controls (Fig. 9C–D).